A new survey by Charles Schwab finds a generational preference among younger Americans for low-cost investments. » Read More
Charles Schwab's Liz Ann Sonders explains why she expects the bull market to continue and what the Federal Reserve will do about it.
The latest data on monthly flows in ETFs show that it's still risk-on for many investors in the stock market.
Exchange-traded funds that track high-yield bond indexes have been the beneficiaries of a cash surge in recent weeks.
Exchange-traded funds are expanding their quest to take over the investing world.
A big part of ETF appeal is low fees, so how do some ETFs get away with charging 1 percent or more? High-fee ETF talk can be cheap.
A total of $149.2 billion is flowing into equity funds, and some are worried, with Matt Hougan, ETF.com CEO.
Tom Lydon, President of Global Trends Investments; Jon Najarian, Co-Founder, OptionMonster.com; and Herb Greenberg, Partner, Pacific Square Research, debate how culpable ETFs are for the market's extreme volatility.
The rise of mutual funds and ETFs focusing on workplace diversity strives to make the case that diversity excels in stock performance.
Eugene Fama, the University of Chicago investing researcher, once again warned investors against the lure of active management.
Bonds may be out of favor, but experts say emerging markets fixed income still offers plenty of value.
A top Wall Streeter thinks the government is hurting the economic recovery by unfairly constraining banks and continuing bad policies.
A top Wall Street investment expert doesn't see a stock or corporate bond crash coming anytime soon—even if it's tough to spot cheap assets.
The age of robots as mankind's master is beginning, but don't be Terminator-terrified. Profit from the rise of the machines.
With 1,600 ETFs on the market, more are pushing the limits of investing (and common) sense. We put some oddball ETFs to the test.
An industry expert explains his big change of heart over adding ETFs to a retirement plan. It's not just hype; 401(k)s do need ETFs.
More money managers think U.S. stocks are frothy, but they continue to find compelling value in other parts of the global market.
Jim Cramer spoke with JJ Bienaimé for more on the company's newest drug that treats a very rare disease.
Jim Cramer looks ahead to a tidal wave of earnings and seeks out buying opportunities.
Infrastructure stocks got a big boost after Trump's election, but the run is "not even beginning," Mario Gabelli says.